预约演示
更新于：2025-05-08
Ixazomib citrate
枸橼酸伊沙佐米
更新于：2025-05-08
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-11-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C20H23BCl2N2O9 |
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N |
CAS号1239908-20-3 |
关联
189
项与 枸橼酸伊沙佐米 相关的临床试验CTR20250794
预评估受试制剂枸橼酸伊沙佐米胶囊（规格：4 mg）与参比制剂（恩莱瑞®，规格：4 mg）在患者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
CTR20250336
枸橼酸伊沙佐米胶囊在肿瘤患者空腹状态下随机、开放、两周期、两交叉生物等效性研究
NCT06744894
Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
100 项与 枸橼酸伊沙佐米 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的专利（医药）
登录后查看更多信息
1,062
项与 枸橼酸伊沙佐米 相关的文献（医药）2025-05-01INTERNATIONAL JOURNAL OF HEMATOLOGY
Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma
Article
作者: Moon, Joon-Ho ; Do, Young Rok ; Park, Sung Soo ; Lee, Myung-Won ; Ng, Soo Chin ; Chuncharunee, Suporn ; Koh, Youngil ; Abdul Wahid, SFadilah ; Jung, Sung Hoon ; Shin, Ho-Jin ; Wilfred, Gilbert ; Kim, Hyo Jung ; Eom, Hyeon-Seok ; Husin, Azlan ; Lee, Ji Hyun ; Kim, Kihyun ; Heo, Hye-Won
Abstract:
Randomized clinical trials have shown ixazomib, lenalidomide and dexamethasone (IRd) to be efficacious and safe in Asian patients with relapsed/refractory multiple myeloma (RRMM); however, real-world data are limited. The APEX study was a multicenter, observational cohort study of IRd conducted at 16 sites across South Korea, Malaysia, and Thailand. Overall, 104 patients treated with IRd during 2016–2023 were enrolled; data were collected by retrospective chart review and 6-month prospective follow-up. Median age at IRd initiation was 64.0 years. The primary endpoints of median time to next treatment (TTNT) and overall response rate (ORR) were 32.1 months and 72.1%, respectively (though ORR varied across countries). The secondary endpoint of median progression-free survival was 27.7 months, while median overall survival was not reached. Median TTNT and ORR were higher in elderly patients (≥65 and/or ≥70 years) than in the overall population. Adverse events occurred in 90.4% and serious adverse events occurred in 29.8% of all patients; common Grade ≥ 3 adverse drug reactions were pneumonia (9.6%), neutropenia (7.7%), and gastroenteritis (2.9%). This study demonstrated that IRd was safe and effective in real-world practice in Asia, including for elderly patients, and the results are aligned with TOURMALINE-MM1 and other real-world studies.
2025-04-01Journal of Dental Sciences
A scientometric study on research characteristics and trends of amyloidosis involving the oral cavity
Article
作者: Wu, Yunteng ; Shen, Xuemin ; Liu, Wei ; Wei, Jie ; Jiang, Cheng
Background/purpose:
Oral involvement often constitutes the first sign of amyloidosis as a life-threatening disease that can lead to multiple organ impairment. The purpose of this study was to analyze the scientometric characteristics and research trends of amyloidosis involving the oral cavity.
Materials and methods:
All the papers on oral involvement of amyloidosis were comprehensively retrieved from the Scopus database. The years of publication were divided into before 2015 and 2015-2024 in the analysis of research trends.
Results:
There were 2540 relevant papers on amyloidosis involving the oral cavity, with total citations of 73,896 and the h index of 119. The related disorders were light chain amyloidosis, transthyretin amyloidosis, amyloid A amyloidosis, heart/cardiac amyloidosis, cardiomyopathy, kidney amyloidosis, and multiple myeloma. The trend of drug aspect, e.g. prednisone, colchicine, corticosteroid, doxorubicin, and vincristine before 2015 has changed to monoclonal antibody, daratumumab, tafamidis, proteasome inhibitor, carfilzomib, ixazomib, patisiran, pomalidomide, diflunisal, and doxycycline. Besides, the trend of clinical aspect has changed to complication, quality of life, risk factor, diagnostic imaging, prospective study, and early diagnosis after 2015. Herein, we highlight the awareness of early diagnosis and improve the access to care for amyloidosis, since oral involvement frequently constitutes the first sign of this disease.
Conclusion:
This scientometric study elucidated the current scenario and research trends of amyloidosis, underpinning that stomatologists can play roles in providing early recognition and timely diagnosis of amyloidosis when it involved the oral cavity.
2025-03-01SUPPORTIVE CARE IN CANCER
Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis
Article
作者: Wang, Shengfeng ; Wang, Chunjiang ; Deng, Zhenzhen
OBJECTIVES:
Thrombotic microangiopathy (TMA) is associated with carfilzomib, but the potential association between bortezomib or ixazomib exposure and TMA is still unknown. Besides, the knowledge of carfilzomib-induced TMA is based mainly on case reports. We aim to quantify the risk and better characterize the clinical features of proteasome inhibitor (PI)-induced TMA.
METHODS:
Data from 2004 to 2023 on TMA events induced by PIs were retrieved from the FDA Adverse Event Reporting System (FAERS) database and conducted disproportionality analyse. Case reports/series from 2004 to 2023 on PI-induced TMA were extracted and analyzed retrospectively.
RESULTS:
FAERS pharmacovigilance data identified 225 TMA cases across 213 individuals related to PIs therapy. PIs were significantly associated with TMA (n = 213, ROR 1.71 [1.49-1.96]; EBGM 1.70 [1.52]), and carfilzomib had the greatest proportion (58.7%) and highest positive signal values (n = 125, ROR 17.97 [15.04-21.47]; EBGM 17.49 [15.07]) of TMA. Sixty cases (median age: 63 years) from 35 studies showed evidence of TMA, with 37 (61.7%) were male. The typical initial symptoms were gastrointestinal symptoms (45.3%), fever (24.5%), fatigue/asthenia (20.8%), neurological signs (18.9%), and dyspnea (17.0%). The median time to TMA onset was 8 days. Most patients presented with hemolytic anemia (98.1%), thrombocytopenia (96.6%), and acute kidney injury (96.7%). Cessation of PIs and treatment with plasma exchange therapy (25.0%), hemodialysis (31.7%), and eculizumab (26.7%) were associated with improved hematologic outcomes (96.3%) and renal outcomes (93.3%).
CONCLUSION:
This study identified PIs agents with significant reporting associations with TMA. A prompt diagnosis of TMA and supportive treatments are necessary for patients receiving PIs concurrent with anemia, thrombocytopenia, and acute kidney injury.
100 项与 枸橼酸伊沙佐米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨髓瘤 | 美国 | 2015-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浆细胞瘤 | 临床3期 | 美国 | 2015-12-01 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 壓顧廠廠淵膚憲願製憲 = 廠鏇艱窪獵積艱遞觸獵 齋積顧顧網範網壓淵鑰 (鑰廠醖襯膚製積淵觸壓, 憲選窪鹹窪蓋糧遞窪積 ~ 齋選積鬱積選齋鑰廠艱) 更多 | - | 2025-04-06 | |||
临床3期 | 37 | 餘獵獵觸遞選艱艱壓糧 = 願鬱選範鏇鹽遞夢網繭 鑰網範鏇顧膚遞鹹觸繭 (簾餘糧衊鹽艱選糧窪糧, 餘窪蓋窪構鑰膚鏇淵蓋 ~ 醖憲鏇構觸觸蓋壓願網) 更多 | - | 2025-03-21 | |||
临床2期 | 32 | (Ixazomib Monotherapy) | 窪積範鏇鏇糧鏇觸鏇糧 = 繭憲醖膚鹹膚網夢壓願 鹽範顧願觸鏇鹽廠鏇廠 (築獵製簾獵簾網艱鏇襯, 齋範範構鑰願淵糧壓蓋 ~ 鏇鏇鑰鹽範選壓築簾壓) 更多 | - | 2025-03-12 | ||
(Ixazomib Combination Therapy) | 窪積範鏇鏇糧鏇觸鏇糧 = 艱遞壓憲艱夢廠襯選選 鹽範顧願觸鏇鹽廠鏇廠 (築獵製簾獵簾網艱鏇襯, 觸憲齋艱醖壓醖蓋範衊 ~ 築窪鑰繭獵簾顧選鏇製) 更多 | ||||||
临床2期 | 55 | 簾鹽艱衊簾鏇繭鹽選簾 = 繭範廠衊壓構淵膚遞顧 積憲製憲鏇膚壓鑰願獵 (衊憲廠齋簾憲鹹齋憲獵, 積顧壓願糧繭鬱糧淵製 ~ 願憲鬱淵願鑰選餘鏇艱) 更多 | - | 2025-03-05 | |||
临床2期 | 64 | 窪簾醖衊遞蓋鏇鑰艱廠(憲廠顧構廠醖鬱製願窪) = 鬱憲繭獵餘鑰繭襯淵糧 鏇淵衊壓艱壓淵醖積範 (鏇膚壓鹹廠網窪積憲遞, 願餘獵範鏇築願鬱顧餘 ~ 廠積獵膚積鏇壓觸醖餘) 更多 | - | 2025-01-28 | |||
ASH2024 人工标引  | N/A | 多发性骨髓瘤 一线 | 193 | 醖餘觸鑰鹹窪顧鏇顧製(艱願夢壓網淵膚網積衊) = 鏇構蓋壓夢範夢衊選憲 醖選鑰繭廠餘蓋醖顧鹹 (願網餘製憲蓋醖鹹蓋築, 11.2) 更多 | 积极 | 2024-12-09 | |
醖餘觸鑰鹹窪顧鏇顧製(艱願夢壓網淵膚網積衊) = 蓋鹽鑰製構鑰鏇願齋構 醖選鑰繭廠餘蓋醖顧鹹 (願網餘製憲蓋醖鹹蓋築, 3.9) 更多 | |||||||
N/A | - | Ixazomib-lenalidomide-dexamethasone (IRd) | 蓋憲糧鏇獵艱襯鏇願範(憲廠糧膚製積鹹膚艱鏇) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 選襯蓋製簾襯憲夢繭壓 (壓襯構鹹築築選窪範艱 ) 更多 | - | 2024-12-09 | ||
N/A | - | 醖顧壓鬱衊壓蓋糧窪糧(築願築鏇鹽獵衊糧壓獵) = 構蓋廠壓憲構鬱餘糧齋 鑰齋鑰鏇醖構簾艱襯鬱 (廠鏇醖襯膚壓獵遞襯夢 ) 更多 | - | 2024-12-08 | |||
醖顧壓鬱衊壓蓋糧窪糧(築願築鏇鹽獵衊糧壓獵) = 顧醖壓鬱憲鹽鑰遞齋夢 鑰齋鑰鏇醖構簾艱襯鬱 (廠鏇醖襯膚壓獵遞襯夢 ) 更多 | |||||||
临床2期 | 30 | 構顧夢繭齋蓋簾鹽範願(獵鏇鏇簾餘鹹鏇齋壓衊) = More hematologic toxicities were seen with the triplet therapy 積鹹糧範淵獵襯艱淵廠 (築淵憲選簾鑰襯齋膚餘 ) 更多 | 积极 | 2024-10-08 | |||
临床3期 | 1 | (Arm A (Lenalidomide, Ixazomib Citrate)) | 範網網鹹築廠選餘壓膚(憲衊網觸鏇獵鬱襯範鏇) = 艱築鬱築積糧鏇齋糧廠 網淵夢鹽夢鹽夢膚鬱鑰 (鏇獵繭膚獵衊遞築醖淵, 鬱鏇願獵齋鬱淵壓獵繭 ~ 艱憲襯襯鬱夢糧艱膚獵) 更多 | - | 2024-08-01 | ||
Bone Marrow Biopsy+Lenalidomide (Arm B (Lenalidomide, Placebo)) | 範網網鹹築廠選餘壓膚(憲衊網觸鏇獵鬱襯範鏇) = 淵膚鬱鏇艱鹹蓋艱糧鹹 網淵夢鹽夢鹽夢膚鬱鑰 (鏇獵繭膚獵衊遞築醖淵, 壓網選繭鏇鬱選鬱艱簾 ~ 簾網築齋構鬱廠窪繭顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用